Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cyclic adenosine monophosphate excretion in urine of patients and carriers of congenital nephrogenic diabetes insipidus


Urinary excretion of cyclic adenosine monophosphate (cAMP) is assessed in response to pitressin stimulation in three patients with nephrogenic diabetes insipidus, four carriers and seven controls. There is no significant difference in cAMP excretion between these groups when corrected for surface area, nor is there any significant increase in excretion after pitressin stimulation. There is very close correlation between urinary cAMP and both urinary concentration and urinary creatinine excretion. Urinary cAMP after pitressin stimulation does not discriminate between carriers of nephrogenic diabetes insipidus and control subjects.

This is a preview of subscription content, log in to check access.


  1. Bell, N. H., Clark, C. M., Avery, S., Sinha, T., Trygstad, C. and Allan, D. D. (1972). Demonstration of defects in the formation of and response to cyclic adenosine 3′,5′-monophosphate in vasopressin-resistant diabetes insipidus.Clin. Res.,20, 586

  2. Bell, N. H., Clark, C. M., Avery, S., Sinha, T., Trygstad, C. and Allen, D. D. (1974). Demonstration of a defect in the formation of adenosine 3′,5′-monophosphate in vasopressin-resistant diabetes insipidus.Pediatr. Res.,8, 223

  3. Broadus, A. E., Kaminsky, N. I., Hardman, J. G., Sutherland, E. W. and Liddle, G. W. (1970). Kinetic parameters and renal clearances of plasma adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate in man.J. Clin. Invest.,49, 2222

  4. Brown, B. L., Ekins, R. E. and Albano, J. D. M. (1972). Saturation assay for cyclic AMP using endogenous binding protein.Adv. Cyclic Nucleotide Res.,2, 25

  5. Carter, C. and Simpkiss, M. (1956). The ‘carrier’ state in nephrogenic diabetes insipidus.Lancet,ii, 1069

  6. Chase, L. R. and Aurbach, G. D. (1968). Renal adenyl cyclase; anatomically separate sites for parathyroid hormone and vaso-pressin.Science,159, 545

  7. Chase, L. R., Melson, G. L. and Aurbach, G. D. (1969). Pseudohypothyroidism: defective excretion of 3′,5′-AMP in response to parathyroid hormone.J. Clin. Invest.,48, 1832

  8. Fichman, M. P. and Brooker, G. (1972). Deficient renal cyclic adenosine 3′,5′-monophosphate production in nephrogenic diabetes insipidus.J. Clin. Endocrinol.,35, 35

  9. Hardman, J. G. (1971). Cyclic GMP and cyclic AMP in urine. In:Cyclic AMP. New York and London: Academic Press

  10. Jones, N. F., Barraclough, M. A., Barnes, N. and Cottom, D. G. (1972). Nephrogenic diabetes insipidus. Effects of 3,5-cyclic-adenosine monophosphate.Arch. Dis. Child.,47, 794

  11. Orloff, J. and Handler, J. (1962). The similarity of effects of vasopressin adenosine 3′,5′-phosphate (cyclic AMP) and theophylline on the toad bladder.J. Clin. Invest.,41, 702

  12. Orloff, J. and Handler, J. (1967). The role of adenosine 3′,5′-phosphate in the action of antidiuretic hormone.Am. J. Med.,42, 757

  13. Porter, G. M. (1974). Investigation of some clinical applications of urinary cyclic AMP determinations. PhD Thesis, University of Edinburgh

  14. Raij, K., Perheentupa, J. and Harkonen, M. (1974). Urinary cyclic adenosine monophosphate excretion in diabetes insipidus of childhood.Scand. J. Clin. Lab. Invest.,34, 177

  15. Royer, P. (1974). The hereditary tubular diseases. In:Paediatric Nephrology (P. Royer, R. Habib, H. Mathieu and M. Broyer, eds.; A. Walsh, transl.). Philadelphia, London and Toronto: W. B. Saunders Co.

  16. Uttley, W. S. and Thistlethwaite, D. (1972). Failure to detect the carrier in congenital nephrogenic diabetes insipidus.Arch. Dis. Child.,47, 137

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Uttley, W.S., Atkinson, B., Adams, A. et al. Cyclic adenosine monophosphate excretion in urine of patients and carriers of congenital nephrogenic diabetes insipidus. J Inherit Metab Dis 1, 75–77 (1978).

Download citation


  • Creatinine
  • Adenosine
  • Control Subject
  • Metabolic Disease
  • Pitressin